MX2014014066A - Compuestos de cromano. - Google Patents

Compuestos de cromano.

Info

Publication number
MX2014014066A
MX2014014066A MX2014014066A MX2014014066A MX2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
alzheimer
disease
preventing
treating diseases
Prior art date
Application number
MX2014014066A
Other languages
English (en)
Spanish (es)
Inventor
Makoto Inoue
Ryosuke Munakata
Kiyohiro Samizu
Shingo Yamasaki
Hisao Hamaguchi
Hiroaki Tominaga
Yasuhiro Shiina
Lin Hong
Original Assignee
Comentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comentis Inc filed Critical Comentis Inc
Publication of MX2014014066A publication Critical patent/MX2014014066A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
MX2014014066A 2012-05-30 2013-05-29 Compuestos de cromano. MX2014014066A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653321P 2012-05-30 2012-05-30
US201361782038P 2013-03-14 2013-03-14
PCT/US2013/043016 WO2013181202A2 (en) 2012-05-30 2013-05-29 Chromane compounds

Publications (1)

Publication Number Publication Date
MX2014014066A true MX2014014066A (es) 2015-03-19

Family

ID=49674034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014066A MX2014014066A (es) 2012-05-30 2013-05-29 Compuestos de cromano.

Country Status (15)

Country Link
US (2) US8975415B2 (enExample)
EP (1) EP2854797A4 (enExample)
JP (1) JP2015518048A (enExample)
KR (1) KR20150023536A (enExample)
CN (1) CN104394862A (enExample)
AR (1) AR091203A1 (enExample)
AU (1) AU2013267555A1 (enExample)
BR (1) BR112014029597A2 (enExample)
CA (1) CA2873678A1 (enExample)
EA (1) EA026380B1 (enExample)
HK (1) HK1208817A1 (enExample)
MX (1) MX2014014066A (enExample)
SG (1) SG11201407796YA (enExample)
TW (1) TW201408672A (enExample)
WO (1) WO2013181202A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181202A2 (en) 2012-05-30 2013-12-05 Astellas Pharma Inc. Chromane compounds
UY36347A (es) * 2014-10-07 2016-04-01 Astrazeneca Ab Compuestos y su uso como inhibidores de bace
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
CN110790753B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林对甲苯磺酸盐、其制备方法和应用
CN110713483B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林中间体及艾拉普林的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
EP1448218A4 (en) 2001-10-23 2009-01-14 Oklahoma Med Res Found BETA SECRETASE INHIBITORS AND METHODS OF USE
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2548388A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2010013302A1 (ja) * 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2010030954A1 (en) * 2008-09-11 2010-03-18 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
PT2406240E (pt) * 2009-03-13 2016-02-24 Boehringer Ingelheim Int Inibidores de beta-secretase
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
WO2011072064A1 (en) * 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
CN102812005B (zh) * 2010-02-24 2014-12-10 生命医药公司 β-分泌酶抑制剂
ES2450568T3 (es) * 2010-03-15 2014-03-25 Amgen Inc. Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
CA2791281A1 (en) * 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
US20120065195A1 (en) * 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
UY33627A (es) 2010-09-24 2013-04-30 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β-分泌酶活性之噁二唑化合物及其使用方法
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2780321B1 (en) 2011-10-10 2015-12-30 Astrazeneca AB Mono-fluoro beta-secretase inhibitors
WO2013181202A2 (en) 2012-05-30 2013-12-05 Astellas Pharma Inc. Chromane compounds
EP2669286A1 (en) 2012-05-31 2013-12-04 Ares Trading S.A. Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
TW201408672A (zh) 2014-03-01
AR091203A1 (es) 2015-01-21
US20140179695A1 (en) 2014-06-26
CA2873678A1 (en) 2013-12-05
HK1208817A1 (en) 2016-03-18
EP2854797A2 (en) 2015-04-08
WO2013181202A2 (en) 2013-12-05
KR20150023536A (ko) 2015-03-05
JP2015518048A (ja) 2015-06-25
WO2013181202A3 (en) 2014-01-30
EA026380B1 (ru) 2017-04-28
SG11201407796YA (en) 2014-12-30
CN104394862A (zh) 2015-03-04
AU2013267555A1 (en) 2014-12-04
EA201492271A1 (ru) 2015-10-30
US20150225386A1 (en) 2015-08-13
US8975415B2 (en) 2015-03-10
US9242973B2 (en) 2016-01-26
EP2854797A4 (en) 2016-01-13
BR112014029597A2 (pt) 2017-11-07

Similar Documents

Publication Publication Date Title
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
MX2014014066A (es) Compuestos de cromano.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2012010084A (es) Compuestos utiles para tratar transtornos neurodegenerativos.
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX365292B (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
WO2012038850A8 (en) Pyrimidones for treatment of potassium channel related diseases
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
GB201206984D0 (en) New therapeutic use
IN2014DN10683A (enExample)
WO2014172453A3 (en) Novel compositions useful in treating brain-related diseases or disorders and methods using same